▼Naloxegol for opioid-induced constipation.

Abstract

▼Naloxegol (Moventig-AstraZeneca) is a peripherally acting mu-opioid receptor antagonist licensed for the treatment of opioid-induced constipation in adults who have had an inadequate response to laxative treatment. It was launched in the United Kingdom in October 2015. Here, we review the evidence for naloxegol and consider its place in the management of opioid-induced constipation.

• Journal: Drug and therapeutics bulletin (Drug Ther Bull) Vol. 53 Issue 12 Pg. 138-40 (Dec 2015) ISSN: 1755-5248 [Electronic] England
• PMID: 26660436 (Publication Type: Journal Article, Review)
• Copyright: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Chemical References

• Analgesics, Opioid
• Morphinans
• Narcotic Antagonists
• Polyethylene Glycols
• naloxegol

Topics

• Analgesics, Opioid (adverse effects)
• Constipation (chemically induced, drug therapy)
• Humans
• Morphinans (adverse effects, therapeutic use)
• Narcotic Antagonists (therapeutic use)
• Polyethylene Glycols (adverse effects, therapeutic use)